Home Stock

Stock Research: United Therapeutics

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

United Therapeutics

NSQ:UTHR US91307C1027
85
  • Value
    7
  • Growth
    62
  • Safety
    Safety
    96
  • Combined
    60
  • Sentiment
    97
  • 360° View
    360° View
    85
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

United Therapeutics Corporation is a pharmaceutical company. They focus on commercial therapies for pulmonary arterial hypertension (PAH) and also have an oncology product. The company operates in the pharmaceutical industry, with products like Tyvaso DPI and Remodulin. In the last fiscal year, the company had a market cap of $13,318 million, profits of $2,568 million, and revenue of $2,877 million, with 1305 employees.

more

ANALYSIS: With an Obermatt 360° View of 85 (better than 85% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock United Therapeutics are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for United Therapeutics. The consolidated Growth Rank has a good rank of 60, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. This means that growth is higher than for 60% of competitors in the same industry. The consolidated Safety Rank at 96 means that the company has a financing structure that is safer than 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, the consolidated Sentiment Rank has a good rank of 95, which means that professional investors are more optimistic about the stock than for 95% of alternative investment opportunities. But the consolidated Value Rank is less desirable at 7, meaning that the share price of United Therapeutics is on the higher side compared with indicators such as revenues, profits, and invested capital. This means the stock price is higher than for 93% of alternative stocks in the same industry. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Liquidity
Country USA
Industry Biotechnology
Size Large
Website unither.com
Index
NASDAQ
D.J. US Health Care
S&P MIDCAP
United Therapeutics stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 8-Jun-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
7 22 n/a n/a
Growth
62 77 n/a n/a
Safety
Safety
96 89 n/a n/a
Sentiment
97 88 n/a n/a
360° View
360° View
85 88 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
30 34 n/a n/a
Opinions Change
78 47 n/a n/a
Pro Holdings
n/a 100 n/a n/a
Market Pulse
100 93 n/a n/a
Sentiment
97 88 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
7 22 n/a n/a
Growth
62 77 n/a n/a
Safety Safety
96 89 n/a n/a
Combined
60 74 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
53 17 n/a n/a
Price vs. Earnings (P/E)
14 53 n/a n/a
Price vs. Book (P/B)
47 44 n/a n/a
Dividend Yield
1 1 n/a n/a
Value
7 22 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
30 56 n/a n/a
Profit Growth
98 59 n/a n/a
Capital Growth
15 59 n/a n/a
Stock Returns
76 91 n/a n/a
Growth
62 77 n/a n/a
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
42 69 n/a n/a
Refinancing
89 49 n/a n/a
Liquidity
100 96 n/a n/a
Safety Safety
96 89 n/a n/a

Similar Stocks

Discover high‑ranked alternatives to United Therapeutics and broaden your portfolio horizons.

Aramark

NYQ:ARMK
Country: USA
Industry: Restaurants
Size: X-Large
Full Stock Analysis

Penske Automotive

NYQ:PAG
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

Regeneron Pharmaceuticals

NSQ:REGN
Country: USA
Industry: Biotechnology
Size: Large
Full Stock Analysis

Marriott Vacations

NYQ:VAC
Country: USA
Industry: Hotels, Resorts & Cruise Lines
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This stock offers a high growth opportunity with safe financing and positive sentiment. It is typically expensive (low Value Rank), as investors pay a premium for high performance. It is for growth-focused investors comfortable paying a premium for a stock with strong future momentum.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews